Home World News EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for...

EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL

April 3, 2025

1019

New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma